ACSL4 and hepatocellular carcinoma: In contrast, increased expression of the ferroptosis marker ACSL4 positively correlates with complete or partial therapy responses in human HCC patients treated with the clinically approved kinase inhibitor sorafenib [20], although it is currently under debate whether sorafenib is capable of inducing ferroptosis in HCC cells [21].